Psychosis to Pancreatitis: A Case Study Exploring the Risks of Hypertriglyceridemia in a Patient Treated With Olanzapine
- PMID: 39483579
- PMCID: PMC11527500
- DOI: 10.7759/cureus.70585
Psychosis to Pancreatitis: A Case Study Exploring the Risks of Hypertriglyceridemia in a Patient Treated With Olanzapine
Abstract
Olanzapine is an antipsychotic medication that is used in the management of schizophrenia and bipolar disorder, but it is not without any adverse effects. We present the following case of a 24-year-old man with a history of schizoaffective disorder, obesity, and anxiety, who developed hypertriglyceridemia-induced acute pancreatitis after six months on olanzapine. Despite his adherence to the medication, routine metabolic monitoring was not performed leading to a delayed diagnosis of hypertriglyceridemia and subsequent complications. The case underscores the critical need for regular metabolic monitoring in patients prescribed olanzapine to prevent severe adverse effects and guide timely intervention. Enhanced adherence to monitoring guidelines and consideration of alternative treatments may help mitigate such risks.
Keywords: diabetes; hypertriglyceridemia induced pancreatitis; lipids; psychosis; severe pancreatitis.
Copyright © 2024, Espiridion et al.
Conflict of interest statement
Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
Figures

References
-
- Diagnostic and statistical manual of mental disorders: DSM-5. Arlington, VA: American Psychiatric Association; 2013.
-
- Willner K, Vasan S, Patel P, Abdijadid S. StatPearls. Vol. 8. Treasure Island (FL): StatPearls Publishing; 2024. Atypical antipsychotic agents; p. 2024. - PubMed
-
- Metabolic syndrome and obesity among users of second generation antipsychotics: a global challenge for modern psychopharmacology. Rojo LE, Gaspar PA, Silva H, Risco L, Arena P, Cubillos-Robles K, Jara B. Pharmacol Res. 2015;101:74–85. - PubMed